Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial comparing IMRT + TP, IMRT + weekly cisplatin, and 3D-CRT + weekly cisplatin in locally advanced cervical cancer
ChiCTR-IIR-17012830Phase 3Recruiting
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin and paclitaxel in Cervical Cancer (CC) (3 arms), sponsored by Affiliated Cancer Hospital of Shantou University Medical College. Primary endpoint: Acute hematological toxicity. Started Jan 2016; status: recruiting.
02
Drugs
cisplatinpaclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR-IIR-17012830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012830.